EUDA Health Terminates $10M At-The-Market Offering, Removing Dilution Overhang
EUDA has more than doubled off its 52-week low of $5.26.
Summary
EUDA Health Holdings has terminated its $10 million At-The-Market offering, effective July 22, 2026, removing the potential for significant share dilution as no shares were sold under the program.
Key Events · Financing and Capital Events · EUDA
-
ATM Offering Terminated
EUDA Health Holdings has terminated its At-The-Market (ATM) offering agreement with Chardan Capital Markets LLC, effective July 22, 2026.
-
Potential Dilution Removed
Crucially, no ordinary shares were sold under the $10 million ATM program, which represented a potential dilution of over 25% of the company's market capitalization. This removes a significant overhang on the stock.
-
Immediate Suspension
The company has suspended the ATM offering as of June 10, 2026, ahead of the formal termination date.
Analysis · EUDA · Industrial Applications And Services
EUDA Health Holdings has terminated its At-The-Market (ATM) offering agreement, which allowed it to sell up to $10 million in ordinary shares. This action removes a significant potential source of dilution for existing shareholders, as no shares were sold under the program, thereby eliminating a substantial overhang on the stock. The termination follows a period where the company faced a Nasdaq delisting threat and a going concern warning, but recently regained compliance.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 29.3% of the 1612 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EUDA was trading at $15.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $5.26 to $86.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.